Company:  INTERSECT ENT, INC. (XENT)
Form Type:  8-K
Filing Date:  9/18/2020 
CIK:  0001271214 
Address:  1555 ADAMS DRIVE 
City, State, Zip:  MENLO PARK, California 94025 
Telephone:  650-641-2100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$16.12  
Change: 
0.10 (0.62%)  
Trade Time: 
Oct 23  
Market Cap: 
$527.16M
Trade XENT now with 

© 2020  
Description of Business
We are a commercial drug delivery company transforming care for patients with ear, nose and throat ("ENT") conditions. Our U.S. Food and Drug Administration, or FDA, approved products are steroid releasing implants designed to treat adult patients suffering from chronic sinusitis, who are managed by ENT physicians. These products include our PROPEL ® family of products (PROPEL ® , PROPEL ® Mini and PROPEL ® Contour) and the SINUVA ® (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients in conjunction with sinus surgery primarily in hospitals and ambulatory surgery centers and SINUVA is designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02 Departure of Directors or Certain Officers; ...
    SIGNATURES